BlueShield of Northeastern New York also understands that Regranex is an expensive alternative wound care therapy that is marginally more effective than alternatives: “Notes: • In a randomized, double-blind study of Regranex® gel (100mcg/g once daily for 16 weeks) in patients with Stage III or IV pressure ulcers, the incidence of complete ulcer closure was 15% (28/189) in the becaplermin group and 12% in the vehicle control group. [read post]